Aerie Pharmaceuticals, Inc. (Aerie), has begun patient dosing in their first human clinical trial of a sustained release implant in patients with wet macular degeneration or diabetic macular edema. The polymer implant provides controlled release of AR-13503, an injectable drug that inhibits blood vessel growth in the retina, while potentially reducing the treatment burden associated with more frequent intravitreal injections.
The study is designed to confirm the usefulness of AR-13503 either as a monotherapy or in combination with anti-VEGF drugs. More information about the study is available at www.clinicaltrials.gov.
Information about all leading anti-angiogenic drug studies may be found here.